Table 1 Recipient characteristics and model CTC viability in their blood specimens preserved for 7 days
From: Zwitterionic microgel preservation platform for circulating tumor cells in whole blood specimen
Recipient characteristics | Model CTC viability | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age | Blood type | Cancer stage | ZBVA hydrogel | CPDA | ||||||||
Day1 | Day3 | Day5 | Day7 | Day1 | Day3 | Day5 | Day7 | |||||
Patient-1 | 58 | B | IIIA | 91% | 87% | 79% | 73% | 34% | 22% | 13% | 6% | |
Patient-2 | 61 | A | IIA | 92% | 88% | 78% | 75% | 42% | 15% | 7% | 8% | |
Patient-3 | 47 | B | 0 | 94% | 88% | 81% | 64% | 30% | 32% | 10% | 7% | |
Patient-4 | 68 | O | IIIA | 92% | 86% | 75% | 54% | 33% | 39% | 8% | 8% | |
Patient-5 | 58 | B | IIA | 97% | 81% | 78% | 76% | 30% | 30% | 9% | 6% | |
Patient-6 | 46 | A | IIA | 97% | 84% | 69% | 71% | 32% | 27% | 9% | 7% | |
Patient-7 | 39 | AB | IIB | 94% | 83% | 74% | 52% | 75% | 26% | 13% | 4% | |
Patient-8 | 43 | O | IA | 98% | 89% | 84% | 74% | 73% | 32% | 9% | 8% | |
Patient-9 | 52 | AB | IB | 93% | 89% | 68% | 81% | 67% | 23% | 9% | 6% | |
Patient-10 | 68 | AB | IIA | 95% | 85% | 78% | 64% | 29% | 18% | 4% | 7% | |
Patient-11 | 68 | A | IIIB | 94% | 89% | 80% | 63% | 71% | 45% | 4% | 7% | |
Patient-12 | 54 | O | IIIA | 95% | 90% | 81% | 60% | 30% | 44% | 3% | 11% | |
Patient-13 | 36 | B | IIA | 94% | 90% | 80% | 46% | 54% | 9% | 5% | 7% | |
Patient-14 | 44 | O | IA | 90% | 88% | 81% | 44% | 50% | 40% | 5% | 6% | |
Patient-15 | 39 | B | IIIB | 91% | 87% | 79% | 53% | 59% | 13% | 9% | 5% | |
Patient-16 | 38 | A | IA | 93% | 88% | 70% | 63% | 54% | 29% | 7% | 7% | |
Patient-17 | 35 | AB | IIB | 88% | 88% | 78% | 73% | 60% | 37% | 8% | 5% | |
Patient-18 | 46 | O | IIA | 91% | 86% | 72% | 74% | 51% | 24% | 7% | 0% | |
Patient-19 | 44 | B | 0 | 89% | 88% | 74% | 75% | 61% | 27% | 8% | 8% | |
Patient-20 | 62 | B | IIA | 92% | 87% | 78% | 72% | 44% | 0% | 9% | 3% | |
